Basilea Pharmaceutica AG BASILEA .../ CH0011432447 /
| 5/24/2024 4:57:06 PM | Chg. - | Volume | Bid6:00:03 AM | Ask6:00:03 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 43.65CHF | - | 604 Turnover: 1,788.45 |
-Bid Size: - | -Ask Size: - | 616.35 mill.CHF | - | 54.08 |
GlobeNewswire
8/27
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) an...
GlobeNewswire
8/21
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
8/13
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and prof...
GlobeNewswire
7/25
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOL...
GlobeNewswire
6/20
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Newsfile Corp
6/18
GNQ Insilico's AI-Driven Digital Twin Platform Shows Promising Results in First Virtually Simulated ...
GlobeNewswire
6/2
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT...
GlobeNewswire
5/28
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire
5/21
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipelin...
GlobeNewswire
5/16
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
5/14
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 f...
GlobeNewswire
5/3
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire
4/24
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire
4/17
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
GlobeNewswire
4/9
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
4/4
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire
4/2
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for t...
GlobeNewswire
3/11
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire
2/13
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
GlobeNewswire
2/13
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
1/29
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Pha...
